论文部分内容阅读
从1978年6月起我们应用广西医药研究所提供的美登木注射液(M_2)治疗20例原发性肝癌并观察1年半时间,有6例病人延长生存时间达1年4个月以上,4例仍有一定的劳动力,有2例血胎甲蛋白阴转。因此,我们认为M_2对原发性肝癌有一定疗效,现将结果报告如下: 病例来源及诊断依据 20例中有14例为在田东县普查时发现,6例为住院病人。男15例,女5例。年龄为27～70岁,其中27～40岁7例,40岁以上为13例。小学教员2例,当地农民18例。诊断
From June 1978, we applied 20 patients with primary hepatocellular carcinoma treated by Meisngmu Injection (M_2) provided by Guangxi Institute of Medicine and observed one and a half years, and 6 patients prolonged their survival time by more than 1 year and 4 months , 4 cases still have a certain amount of labor, 2 cases of blood protein A negative transfer. Therefore, we believe that M_2 has a certain effect on primary liver cancer, the results are reported as follows: Source and diagnosis of cases based on 20 of 14 cases were found in Tiandong County census, 6 were hospitalized patients. 15 males and 5 females. Aged 27 to 70 years old, of which 27 to 40 years old in 7 cases, more than 40 years old in 13 cases. 2 primary school teachers, 18 local farmers. diagnosis